Broncus Holding (HKSE:02216) ROCE % : -8.66% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Broncus Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Broncus Holding's annualized ROCE % for the quarter that ended in Jun. 2024 was -8.66%.

Broncus Holding ROCE % Historical Data

The historical data trend for Broncus Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Broncus Holding ROCE % Chart

Broncus Holding Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-407.59

-286.85

-175.25

-12.18

-13.95

Broncus Holding Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial					-13.64	-10.76	-14.27	-13.73	-8.66

Broncus Holding ROCE % Calculation

Broncus Holding's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-218.096	/	( ( (1727.907 - 57.744)	+	(1529.198 - 71.522) )	/ 2 )
	=	-218.096	/	( (1670.163	+	1457.676)	/ 2 )
	=	-218.096	/	1563.9195
	=	-13.95 %

Broncus Holding's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-123.242	/	( ( (1529.198 - 71.522)	+	(1443.194 - 52.999) )	/ 2 )
	=	-123.242	/	( ( 1457.676	+	1390.195 )	/ 2 )
	=	-123.242	/	1423.9355
	=	-8.66 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Broncus Holding (HKSE:02216) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Broncus Holding ROCE % Related Terms

Thank you for viewing the detailed overview of Broncus Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Broncus Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN

Website

https://www.broncus.com

Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.

Executives

Xu Hong	2101 Beneficial owner
Zi Zhenjun
Xin Nuo Tong Investment Limited	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qm12 Limited	2101 Beneficial owner
Dinova Capital Limited
Dinova Venture Partners Gp Iii, L.p.
Broncus Biomedical Limited
Dinova Healthcare Gamma Fund (usd) L.p.
Computershare Hong Kong Trustees Limited	2301 Trustee
Dinova Healthcare (hong Kong) Co., Limited
Lake Bleu Capital (hong Kong) Limited	2102 Investment manager
Hang Zhou De Nuo Shang Wu Zi Xun Zi Xun You Xian Gong Si

Broncus Holding Headlines

No Headlines